Home > Pulmonology > Oral cannabinoid drugs may worsen COPD outcomes

Oral cannabinoid drugs may worsen COPD outcomes


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Thorax
Reuters Health - 27/10/2020 - Using prescription oral cannabinoid drugs is associated with increased rates of adverse outcomes in older patients with chronic obstructive pulmonary disease (COPD), a new study shows. COPD patients increasingly use prescription synthetic oral cannabinoid drugs to treat chronic musculoskeletal pain, insomnia and refractory dyspnea, though there is little evidence to support such use, according to Dr. Nicholas T. Vozoris of the University of Toronto, in Canada, and colleagues. Using data from the ICES health administrative database for the province of Ontario and linked databases, the researchers evaluated respiratory morbidity and mortality in people 66 years and older with COPD who had been prescribed nabilone or dronabinol, two synthetic oral cannabinoid drugs. They focused on the first 60 days after the drugs were dispensed. In the overall analysis, new cannabinoid use was not associated with increased hospitalizations for COP...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on